scPharmaceuticals (SCPH) Stock Price, News & Analysis

Company Overview

scPharmaceuticals, Inc. is a clinical‐stage biopharmaceutical company focused on developing innovative therapies for sickle cell disease. The company’s lead product candidate, SC411, is an investigational intravenous formulation of a hemoglobin polymerization inhibitor designed to rapidly increase hemoglobin oxygen affinity and potentially reduce the severity and duration of vaso‐occlusive crises. By delivering a water‐soluble prodrug directly into the bloodstream, scPharmaceuticals aims to address an acute unmet need in emergency and inpatient settings where swift intervention can improve patient outcomes.

In addition to SC411, scPharmaceuticals is advancing a pipeline of small‐molecule candidates that target different aspects of red blood cell pathology in sickle cell disease. The company’s research and development efforts leverage proprietary prodrug technology to enhance delivery and bioavailability, with the goal of providing both acute crisis interventions and chronic disease management options. scPharmaceuticals collaborates with academic institutions and clinical research organizations to conduct Phase 1 studies and plans to initiate later‐stage trials upon successful completion of early safety and pharmacokinetic assessments.

Headquartered in Cambridge, Massachusetts, scPharmaceuticals was founded to translate cutting‐edge science into practical treatments for patients suffering from sickle cell disease. The company’s leadership team comprises industry veterans with experience in hematology, drug development and regulatory affairs. While initially focused on the U.S. market, scPharmaceuticals has stated its intention to expand clinical programs internationally as it progresses toward potential product approvals.

Key Stats

• Today's Range: $5.61 to $5.64
• 50-Day Range: $3.86 to $5.84
• 52-Week Range: $1.94 to $6.28
• Volume: 2.00 million shs
• Average Volume: 609,783 shs
• Market Capitalization: $300.08 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $7.78
• Consensus Rating: Hold

scPharmaceuticals Stock Analysis - MarketRank™

scPharmaceuticals scored higher than 91% of companies evaluated by MarketBeat, and ranked 108th out of 947 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.6 / 5
• Analyst Rating: Hold

Consensus Rating

scPharmaceuticals has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 3 hold ratings, and no sell ratings.

Upside Potential

scPharmaceuticals has a consensus price target of $7.78, representing about 38.4% upside from its current price of $5.63.

Amount of Analyst Coverage

scPharmaceuticals has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for scPharmaceuticals are expected to grow in the coming year, from ($1.53) to ($1.08) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of scPharmaceuticals is -3.11, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of scPharmaceuticals is -3.11, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

scPharmaceuticals has a P/B Ratio of 20.83. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

1.37% of the float of scPharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

scPharmaceuticals has a short interest ratio ("days to cover") of 0.8, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in scPharmaceuticals has recently decreased by 48.16%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

scPharmaceuticals does not currently pay a dividend.

Dividend Growth

scPharmaceuticals does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 4.2 / 5
• Environmental Score: -1.12

Percentage of Shares Shorted

1.37% of the float of scPharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

scPharmaceuticals has a short interest ratio ("days to cover") of 0.8, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in scPharmaceuticals has recently decreased by 48.16%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 3.8 / 5
• News Sentiment: 1.89

News Sentiment

scPharmaceuticals has a news sentiment score of 1.89. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 1.07 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 4 news articles for scPharmaceuticals this week, compared to 2 articles on an average week.

Search Interest

Only 2 people have searched for SCPH on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

MarketBeat Follows

1 people have added scPharmaceuticals to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, scPharmaceuticals insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 4.78% of the stock of scPharmaceuticals is held by insiders.

Percentage Held by Institutions

89.52% of the stock of scPharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

SCPH Stock Analysis - Frequently Asked Questions

How have SCPH shares performed this year?

scPharmaceuticals' stock was trading at $3.54 at the beginning of the year. Since then, SCPH stock has increased by 58.9% and is now trading at $5.6250.

How were scPharmaceuticals' earnings last quarter?

scPharmaceuticals, Inc. (NASDAQ:SCPH) released its earnings results on Thursday, August, 7th. The company reported ($0.34) EPS for the quarter, missing the consensus estimate of ($0.30) by $0.04. The firm earned $16.04 million during the quarter, compared to analysts' expectations of $15.41 million. scPharmaceuticals had a negative net margin of 183.55% and a negative trailing twelve-month return on equity of 1,647.86%.
Read the conference call transcript.

When did scPharmaceuticals IPO?

scPharmaceuticals (SCPH) raised $96 million in an IPO on Friday, November 17th 2017. The company issued 6,400,000 shares at a price of $14.00-$16.00 per share. Jefferies, Leerink Partners and BMO Capital Markets served as the underwriters for the IPO.

Who are scPharmaceuticals' major shareholders?

scPharmaceuticals' top institutional shareholders include Rubric Capital Management LP (8.63%), AIGH Capital Management LLC (7.33%), King Luther Capital Management Corp (6.71%) and Thrivent Financial for Lutherans (1.61%). Insiders that own company stock include Orbimed Advisors Llc and 5Am Partners Iv, Llc.
View institutional ownership trends.

How do I buy shares of scPharmaceuticals?

Shares of SCPH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of scPharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some other companies that scPharmaceuticals investors own include Voyager Therapeutics (VYGR), Waste Connections (WCN), American Water Works (AWK), The RMR Group (RMR), AU Optronics (AUOTY), DiamondRock Hospitality (DRH) and iShares Micro-Cap ETF (IWC).

Company Calendar

• Last Earnings: 8/07/2025
• Today: 9/11/2025
• Next Earnings (Estimated): 11/12/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:SCPH
• CIK: 1604950
• Web: www.scpharma.com
• Phone: (617) 517-0730
• Fax: N/A
• Employees: 30
• Year Founded: N/A

Price Target and Rating

• Average Price Target for scPharmaceuticals: $7.78
• High Price Target: $12.00
• Low Price Target: $5.35
• Potential Upside/Downside: +38.7%
• Consensus Rating: Hold
• Rating Score (0-4): 2.00
• Research Coverage: 3 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.81)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$85.15 million
• Net Margins: -183.55%
• Pretax Margin: -183.55%
• Return on Equity: -1,647.86%
• Return on Assets: -71.76%

Debt

• Debt-to-Equity Ratio: 3.86
• Current Ratio: 3.85
• Quick Ratio: 3.14

Sales & Book Value

• Annual Sales: $36.33 million
• Price / Sales: 8.23
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.27 per share
• Price / Book: 20.78

Miscellaneous

• Outstanding Shares: 53,300,000
• Free Float: 50,750,000
• Market Cap: $299.01 million
• Optionable: Optionable
• Beta: 0.35